Repurposing Safe Drugs to Modulate DNA Repair in CRISPR Editing

Study Background and Research Question

DNA double-strand breaks (DSBs) represent a critical threat to genomic integrity, arising both spontaneously (e.g., from reactive oxygen species) and through exogenous sources such as cancer radiotherapy or CRISPR-Cas genome editing. Cells repair DSBs using several pathways: the error-prone non-homologous end joining (NHEJ), backup microhomology-mediated end joining (MMEJ), and the more precise homology-directed repair (HDR). The relative activity of these pathways determines the outcome of genome editing and the efficacy of therapeutic interventions. Targeted modulation of these repair pathways can improve editing precision, support synthetic lethality in cancer, and enable disease modeling. However, most available modulators are experimental or lack clinical safety profiles. The reference study systematically asked: Can clinically approved drugs be repurposed to specifically alter DNA repair pathway choice in human cells, and what are the translational implications for genome engineering and cancer therapy?

Key Innovation from the Reference Study

The central innovation of the reference study is the use of a large-scale, unbiased drug repurposing screen to identify FDA-approved compounds that either inhibit or enhance distinct DSB repair pathways. By profiling the mutational outcomes after CRISPR-induced DSBs in human induced pluripotent stem cells (hiPSCs), the authors provide a functional map of how clinically safe molecules can be used to shift the balance between NHEJ, MMEJ, and HDR. This approach not only accelerates the application of precision genome editing, but also supports the rational design of synthetic lethality strategies in oncology, where selective pathway inhibition can sensitize cancer cells to DNA damage.

Methods and Experimental Design Insights

The study employed a high-throughput screening workflow using 409B2 hiPSCs engineered to express a doxycycline-inducible Cas9 (iCRISPR). Cells were transfected with guide RNAs (gRNAs) targeting the FRMD7 locus and exposed to over 7,000 drug conditions—each corresponding to an FDA-approved molecule. After drug treatment and genome editing, cell survival was measured by resazurin fluorescence, and DNA was extracted for next-generation sequencing to profile repair outcomes. The editing events were classified by pathway: NHEJ (insertions of 1 bp), MMEJ (deletions ≥2 bp with microhomology), and HDR (precise edits using exogenous templates). This multiplexed design enabled simultaneous quantification of survival, editing efficiency, and pathway usage across thousands of conditions.

• The use of a single gRNA and locus standardized the comparative analysis of editing outcomes.
• Sequencing data were mapped to specific indel signatures to distinguish NHEJ and MMEJ events.
• Cell survival served as a synthetic lethality readout for conditions where key repair pathways were compromised.

Core Findings and Why They Matter

The screen revealed a diverse set of clinically safe drugs capable of modulating the frequency and type of DSB repair events. Notable results include:

• Identification of compounds that selectively enhance HDR, increasing the rate of precise genome edits. For example, silencing of estrogen receptor 2 (ESR2) in combination with NHEJ inhibition achieved a mean 4.6-fold increase in HDR frequency.
• Discovery of drugs that suppress NHEJ or MMEJ, reducing the prevalence of error-prone repair and minimizing deleterious indels.
• Mapping of synthetic lethality interactions—where inhibition of one repair pathway, combined with certain drugs, is selectively toxic to cells lacking a compensatory mechanism. This is particularly relevant for targeting tumor cells with pre-existing repair defects.

These findings have broad translational value. For disease modeling and gene therapy, the ability to pharmacologically steer repair outcomes improves the predictability and safety of CRISPR-based interventions. In oncology, the identification of synthetic lethal drug-pathway pairs supports personalized approaches to cancer treatment, exploiting vulnerabilities unique to tumor cells with repair deficiencies.

Comparison with Existing Internal Articles

The reference study's comprehensive approach is aligned with several internal resources. For example, "Repurposing Approved Drugs to Modulate DNA Repair in CRISPR Editing" also highlights the potential of small molecules to enhance gene editing fidelity and synthetic lethality. Both sources emphasize the utility of human iPSC models and next-generation sequencing for pathway analysis. Additionally, "Repurposing Drugs to Modulate DNA Repair in CRISPR Editing" underscores the translational relevance of these findings to precision medicine workflows. These articles reinforce the reference study’s conclusion that drug-induced pathway modulation is a promising, rapidly deployable strategy for programmable genome modification.

Of note, several internal articles discuss practical approaches for integrating ryanodine receptor antagonists, such as dantrolene sodium salt, into advanced workflows for calcium signaling modulation and CRISPR editing. While the main focus of the reference study is DNA repair, these resources provide context for how modulation of intracellular signaling pathways can intersect with genome editing protocols.

Limitations and Transferability

Despite the breadth of the drug screen, several limitations should be noted. First, the experiments were conducted in a single hiPSC line and at a single genomic locus, which may not fully capture the diversity of repair outcomes seen in primary cells or other genomic contexts. Second, drug concentrations and exposure times were optimized for screening, but may require further adjustment for therapeutic application. Third, the synthetic lethality results are based on cell survival assays and require validation in disease-relevant models and in vivo systems. Finally, while many identified compounds are clinically safe, off-target effects and potential interactions with genome editing reagents must be systematically evaluated before translational deployment.

Protocol Parameters

• Drug screening concentration: Compounds applied at clinically relevant or maximum tolerated plasma levels; further titration recommended for pathway-specific effects.
• Editing window: Doxycycline-induced Cas9 expression for 24–48 hours to synchronize DSB induction with drug exposure.
• DNA repair outcome analysis: Illumina sequencing 3–5 days post-editing to quantify indel and HDR frequencies.
• Cell survival assessment: Resazurin-based viability assay post-drug and -editing intervention to detect synthetic lethality.
• Replicates: One replicate per drug condition in the screen; follow-up validation with biological triplicates is recommended for hit compounds.

Why this cross-domain matters, maturity, and limitations

The bridge between pharmacological modulation of DNA repair and programmable genome editing marks a critical advance in both basic and applied biomedical research. By demonstrating that existing, clinically approved drugs can shift repair pathway choice, the reference study lowers the translational barrier for deploying these interventions in gene therapy and oncology. However, pathway modulation may have cell-type and context-specific effects, and the synthetic lethality paradigm still requires disease-specific validation. The maturity of this approach is high for in vitro screening but remains at the proof-of-principle stage for clinical translation.

Research Support Resources

For researchers seeking to replicate or extend these workflows, several resources are available. Notably, compounds such as Dantrolene, sodium salt (SKU B6329) from APExBIO offer a well-characterized tool for modulating ryanodine receptor-mediated calcium release, intersecting with cellular signaling pathways relevant to DNA repair and stress responses. Dantrolene sodium salt’s high potency as a ryanodine receptor antagonist (IC50 ≈ 5.9 nM for RyR2) and calmodulin-dependent mechanism support its use in advanced calcium signaling modulation and synthetic lethality workflows, as described in the internal literature. Proper storage and handling, including dissolution in DMSO and short-term solution use, are recommended to maintain compound stability and activity. In sum, integrating such research compounds can enhance the reproducibility and mechanistic depth of genome editing and DNA repair pathway studies.